Table 1.
Case series of patients with vaccine-related thrombosis
| Author/year | Number of patients | Age, years | Sex, % female | Type of vaccine | Site of thrombosis |
|---|---|---|---|---|---|
| Schultz (2021)6 | 5 | 32–54 | 80 | ChAdOx1 nCoV-19 | 4 CVT and 1 PVT, left hepatic vein, splenic vein, azygos vein, hemiazygos vein, and several basivertebral veins |
| See (2021)7 | 12 | 18–59 | 100 | Ad26.COV2.S COVID-19 | CVT |
| Greinacher (2021)11 | 11 | 22–49 | 82 | ChAdOx1 nCov-19 |
9 CVT, 3 had splanchnic-vein thrombosis, 3 PE, and 4 had other thrombosesa |
| Vayne (2021)9 | 11 | 44 | NA | ChAdOx1 nCov-19 | 6 CVT, 5 had splanchnic vein thrombosis |
| Scully (2021)8 | 23 | 21–77 | 52 | ChAdOx1 nCov-19 | 15 CVT, 6 PE/DVT, 3 PVTa |
| Wolf (2021)12 | 3 | 22–46 | 100 | ChAdOx1 nCoV-19 | Intracranial venous sinus thrombosis |
| Pottegard (2021)13 |
148 792 in Denmark 132 472 in Norway |
18–65 |
80 in Denmark 78 in Norway |
ChAdOx1 nCoV-19 |
52 cardiac events 27 cerebrovascular events 59 VTE: 7 CVT, 21 PE, 22 DVT Splanchnic thrombosis <5 |
| Castelli (2021)14 | 1 | 20–50 | 0 | ChAdOx1 nCoV-19 | CVT |
CVT, cerebral venous thrombosis; DVT, deep venous thrombosis; PE, pulmonary embolism; PVT, portal vein thrombosis; VTE, venous thromboembolism.
a
Patients had one or more thrombosis.